TC BioPharm Valuation
| TCBP Stock | USD 0.50 1.04 67.53% |
TC BioPharm is overvalued. TC BioPharm Holdings owns a latest Real Value of $0.48 per share. The recent price of the entity is $0.5. Our model measures the value of TC BioPharm Holdings from examining the entity fundamentals such as return on asset of -1.09, and Gross Profit of 3.84 M as well as evaluating its technical indicators and probability of bankruptcy. Key fundamental drivers impacting TC BioPharm's valuation include:
Price Book 0.3194 | Enterprise Value | Enterprise Value Ebitda (0.17) | Price Sales 0.5063 | Enterprise Value Revenue 1.8297 |
Overvalued
Today
Please note that TC BioPharm's price fluctuation is out of control at this time. Calculation of the real value of TC BioPharm Holdings is based on 3 months time horizon. Increasing TC BioPharm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
TC BioPharm's intrinsic value may or may not be the same as its current market price of 0.50, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.5 | Real 0.48 | Hype 0.4 | Naive 0.2 |
The intrinsic value of TC BioPharm's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence TC BioPharm's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of TC BioPharm Holdings helps investors to forecast how TCBP stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of TC BioPharm more accurately as focusing exclusively on TC BioPharm's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use TC BioPharm's intrinsic value based on its ongoing forecasts of TC BioPharm's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against TC BioPharm's closest peers.
TC BioPharm Cash |
|
TCBP Valuation Trend
TC BioPharm's real value is important for investors to make better decisions and a more accurate overall view of TC BioPharm's financial worth over time. Using both TC BioPharm's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
TC BioPharm Total Value Analysis
TC BioPharm Holdings is at this time forecasted to have valuation of 1.67 M with market capitalization of 360.37 K, debt of 1.8 M, and cash on hands of 1.57 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the TC BioPharm fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.67 M | 360.37 K | 1.8 M | 1.57 M |
TC BioPharm Asset Utilization
One of the ways to look at asset utilization of TCBP is to check how much profit was generated for every dollar of assets it reports. TC BioPharm Holdings owns a negative utilization of current and long term assets of -1.09 %, losing $0.0109 for each dollar of current and long term assets held by the entity. Discouraging asset utilization indicates the company is being less competent with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of TC BioPharm Holdings shows how wasteful it operates for each dollar spent on its current and long term assets.TC BioPharm Ownership Allocation
Almost 98.24 % of TC BioPharm outstanding shares are held by general public with 1.76 (percent) by institutions.TC BioPharm Profitability Analysis
Net Loss for the year was (5.91 M) with profit before overhead, payroll, taxes, and interest of 3.84 M.About TC BioPharm Valuation
The stock valuation mechanism determines TC BioPharm's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of TC BioPharm Holdings based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of TC BioPharm. We calculate exposure to TC BioPharm's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of TC BioPharm's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 4.4 M | 3.1 M | |
| Pretax Profit Margin | (0.91) | (0.95) | |
| Operating Profit Margin | (3.61) | (3.80) | |
| Net Loss | (0.31) | (0.32) |
TC BioPharm Growth Indicators
Investing in growth stocks can be very risky. If the company such as TC BioPharm does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 123.6 M | |
| Quarterly Earnings Growth Y O Y | -0.868 | |
| Shares Float | 98.4 M |
TC BioPharm Current Valuation Indicators
TC BioPharm's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final TC BioPharm's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as TC BioPharm, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use TC BioPharm's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes TC BioPharm's worth.Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.